AstraZeneca’s Crestor Targets High Risk Patients, Delivers High Sales
This article was originally published in The Pink Sheet Daily
Executive Summary
Crestor sales grew 47% in the second quarter; entry of generic simvastatin caused some expected “disruption” in the marketplace.
You may also be interested in...
Statin Comparative Studies Needed, Oregon Drug Effectiveness Review Project Suggests
DERP wants comparative-effectiveness study on LDL-c lowering capabilities and adverse events.
Statin Comparative Studies Needed, Oregon Drug Effectiveness Review Project Suggests
DERP wants comparative-effectiveness study on LDL-c lowering capabilities and adverse events.
Abbott/AstraZeneca Come Together Over Statin/Fibrate Combo
Two parallel programs have been initiated in search of the next combination cholesterol management drug.